Drugs that contain Meropenem; Vaborbactam
1. Drug name - VABOMERE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8680136 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| CN103180328B | REMPEX | Cyclic Borate Ester Derivatives And Therapeutic Use Thereof Formula Refers To Dda00002980358600011.Gif |
Aug, 2031
(8 years from now) | |
| CN103180328A | REMPEX | Ring Boron Acid Ester Derivatives And Their Therapeutic Use |
Aug, 2031
(8 years from now) | |
| IN391496B | REMPEX | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| IN201301146P1 | REMPEX | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| EP3666778A1 | REMPEX | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| EP3666778B1 | REMPEX | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| EP3412676A1 | REMPEX | Cyclic Boronic Acid Ester Derivatives, Method For The Preparation And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| EP3412676B1 | REMPEX | Cyclic Boronic Acid Ester Derivatives, Method For The Preparation And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| EP2603514A1 | REMPEX | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| EP2603514B1 | REMPEX | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| EP2603514A4 | REMPEX | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof |
Aug, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(8 years from now) | |
| US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US10172874 | REMPEX | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(8 years from now) | |
Treatment: Treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms; Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae species complex; Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, enterobacter cloacae species complex with meropenem & vaborbactam as specified
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 1GM/VIAL;1GM/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.